Please cite this article in press Tanuja M. Langote et al., Treatment And Management Of Leprosy.,Indo Am. J. P. Sci, 2025; 12 (01).

1. Eiglmeier K, Parkhill J, Honoré N, Garnier T, Tekaia F, Telenti A, Klatser P, James KD, Thomson NR, Wheeler PR, Churcher C, Harris D, Mungall K, Barrell BG, Cole ST. The decaying genome of Mycobacterium leprae. Lepr Rev. 2001 Dec;72(4):387-98.
2. Global leprosy situation, 2012. WklyEpidemiol Rec. 2012 Aug 24;87(34):317-28.
3. Truman RW, Singh P, Sharma R, Busso P, Rougemont J, Paniz-Mondolfi A, Kapopoulou A, Brisse S, Scollard DM, Gillis TP, Cole ST. Probable zoonotic leprosy in the southern United States. N Engl J Med. 2011 Apr 28;364(17):1626-33.
4. Domozych R, Kim E, Hart S, Greenwald J. Increasing incidence of leprosy and transmission from armadillos in Central Florida: A case series. JAAD Case Rep. 2016 May;2(3):189-92.
5. Sharma R, Singh P, Loughry WJ, Lockhart JM, Inman WB, Duthie MS, Pena MT, Marcos LA, Scollard DM, Cole ST, Truman RW. Zoonotic Leprosy in the Southeastern United States. Emerg Infect Dis. 2015 Dec;21(12):2127-34.
6. Abraham S, Mozhi NM, Joseph GA, Kurian N, Rao PS, Job CK. Epidemiological significance of first skin lesion in leprosy. Int J Lepr Other Mycobact Dis. 1998 Jun;66(2):131-9.
7. Araujo S, Freitas LO, Goulart LR, Goulart IM. Molecular Evidence for the Aerial Route of Infection of Mycobacterium leprae and the Role of Asymptomatic Carriers in the Persistence of Leprosy. Clin Infect Dis. 2016 Dec 01;63(11):1412-1420.
8. Britton WJ, Lockwood DN. Leprosy. Lancet. 2004 Apr 10;363(9416):1209-19.
9. Lahiri R, Krahenbuhl JL. The role of free-living pathogenic amoeba in the transmission of leprosy: a proof of principle. Lepr Rev. 2008 Dec;79(4):401-9.
10. Paling S, Wahyuni R, Ni’matuzahroh, Winarni D, Iswahyudi, Astari L, Adriaty D, Agusni I, Izumi S. ACANTHAMOEBA SP. S-11 PHAGOCYTOTIC ACTIVITY ON MYCOBACTERIUM LEPRAE IN DIFFERENT NUTRIENT CONDITIONS. Afr J Infect Dis. 2018;12(1 Suppl):44-48.
11. Wheat WH, Casali AL, Thomas V, Spencer JS, Lahiri R, Williams DL, McDonnell GE, Gonzalez-Juarrero M, Brennan PJ, Jackson M. Long-term survival and virulence of Mycobacterium leprae in amoebal cysts. PLoSNegl Trop Dis. 2014 Dec;8(12):e3405.
12. Moss C, Burn J. Genetic counselling in hypomelanosis of Ito: case report and review. Clin Genet. 1988 Aug;34(2):109-15.
13. Van Beers SM, Hatta M, Klatser PR. Patient contact is the major determinant in incident leprosy: implications for future control. Int J Lepr Other Mycobact Dis. 1999 Jun;67(2):119-28.
14. Moet FJ, Pahan D, Schuring RP, Oskam L, Richardus JH. Physical distance, genetic relationship, age, and leprosy classification are independent risk factors for leprosy in contacts of patients with leprosy. J Infect Dis. 2006 Feb 01;193(3):346-53.
15. Moet FJ, Pahan D, Schuring RP, Oskam L, Richardus JH. Physical distance, genetic relationship, age, and leprosy classification are independent risk factors for leprosy in contacts of patients with leprosy. J Infect Dis. 2006 Feb 01;193(3):346-53.
16. Mira MT, Alcaïs A, Nguyen VT, Moraes MO, Di Flumeri C, Vu HT, Mai CP, Nguyen TH, Nguyen NB, Pham XK, Sarno EN, Alter A, Montpetit A, Moraes ME, Moraes JR, Doré C, Gallant CJ, Lepage P, Verner A, Van De Vosse E, Hudson TJ, Abel L, Schurr E. Susceptibility to leprosy is associated with PARK2 and PACRG. Nature. 2004 Feb 12;427(6975):636-40.
17. Trindade MA, Palermo ML, Pagliari C, Valente N, Naafs B, Massarollo PC, D’Albuquerque LA, Benard G. Leprosy in transplant recipients: report of a case after liver transplantation and review of the literature. Transpl Infect Dis. 2011 Feb;13(1):63-9.
18. Martiniuk F, Rao SD, Rea TH, Glickman MS, Giovinazzo J, Rom WN, Cabrera A, Levis WR. Leprosy as immune reconstitution inflammatory syndrome in HIV-positive persons. Emerg Infect Dis. 2007 Sep;13(9):1438-40.
19. Scollard DM, Joyce MP, Gillis TP. Development of leprosy and type 1 leprosy reactions after treatment with infliximab: a report of 2 cases. Clin Infect Dis. 2006 Jul 15;43(2):e19-22.
20. Massone C, Belachew WA, Schettini A. Histopathology of the lepromatous skin biopsy. Clin Dermatol. 2015 Jan-Feb;33(1):38-45.
21. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis. 1966 Jul-Sep;34(3):255-73.
22. Pardillo FE, Fajardo TT, Abalos RM, Scollard D, Gelber RH. Methods for the classification of leprosy for treatment purposes. Clin Infect Dis. 2007 Apr 15;44(8):1096-9.
23. Elinav H, Palladas L, Applbaum YH, Gilead L, Moses AE, Cohen-Poradosu R. Plantar ulcers and eyebrow-hair paucity. Clin Infect Dis. 2006 Mar 01;42(5):684-5, 722-4.
24. Lane JE, Balagon MV, Dela Cruz EC, Abalos RM, Tan EV, Cellona RV, Sadaya PG, Walsh GP, Walsh DS. Mycobacterium leprae in untreated lepromatous leprosy: more than skin deep. Clin Exp Dermatol. 2006 May;31(3):469-70.
25. Kumar B, Rai R, Kaur I. Systemic involvement in leprosy and its significance. Indian J Lepr. 2000 Jan-Mar;72(1):123-42.
26. Fleury RN, Duerksen F. Emergency in leprosy: involvement of the larynx. Lepr Rev. 2007 Jun;78(2):148-50.
27. Saunderson P, Bizuneh E, Leekassa R. Neuropathic pain in people treated for multibacillary leprosy more than ten years previously. Lepr Rev. 2008 Sep;79(3):270-6.
28. Lasry-Levy E, Hietaharju A, Pai V, Ganapati R, Rice AS, Haanpää M, Lockwood DN. Neuropathic pain and psychological morbidity in patients with treated leprosy: a cross-sectional prevalence study in Mumbai. PLoSNegl Trop Dis. 2011 Mar 08;5(3):e981.
29. Wilder-Smith EP, Van Brakel WH. Nerve damage in leprosy and its management. Nat Clin Pract Neurol. 2008 Dec;4(12):656-63.
30. Meima A, Saunderson PR, Gebre S, Desta K, Habbema JD. Dynamics of impairment during and after treatment: the AMFES cohort. Lepr Rev. 2001 Jun;72(2):158-70.
31. Richardus JH, Nicholls PG, Croft RP, Withington SG, Smith WC. Incidence of acute nerve function impairment and reactions in leprosy: a prospective cohort analysis after 5 years of follow-up. Int J Epidemiol. 2004 Apr;33(2):337-43.
32. Saunderson P, Gebre S, Desta K, Byass P, Lockwood DN. The pattern of leprosy-related neuropathy in the AMFES patients in Ethiopia: definitions, incidence, risk factors and outcome. Lepr Rev. 2000 Sep;71(3):285-308.
33. Van Brakel WH, Nicholls PG, Wilder-Smith EP, Das L, Barkataki P, Lockwood DN., INFIR Study Group. Early diagnosis of neuropathy in leprosy—comparing diagnostic tests in a large prospective study (the INFIR cohort study). PLoSNegl Trop Dis. 2008 Apr 02;2(4):e212.
34. Scollard DM. The biology of nerve injury in leprosy. Lepr Rev. 2008 Sep;79(3):242-53.
35. Scollard DM. Time and change: new dimensions in the immunopathologic spectrum of leprosy. Ann Soc Belg Med Trop. 1993;73 Suppl 1:5-11.
36. Lockwood DN, Lucas SB, Desikan KV, Ebenezer G, Suneetha S, Nicholls P. The histological diagnosis of leprosy type 1 reactions: identification of key variables and an analysis of the process of histological diagnosis. J Clin Pathol. 2008 May;61(5):595-600.
37. Ranque B, Nguyen VT, Vu HT, Nguyen TH, Nguyen NB, Pham XK, Schurr E, Abel L, Alcaïs A. Age is an important risk factor for onset and sequelae of reversal reactions in Vietnamese patients with leprosy. Clin Infect Dis. 2007 Jan 01;44(1):33-40.
38. Walker SL, Sales AM, Butlin CR, Shah M, Maghanoy A, Lambert SM, Darlong J, Rozario BJ, Pai VV, Balagon M, Doni SN, Hagge DA, Nery JAC, Neupane KD, Baral S, Sangma BA, Alembo DT, Yetaye AM, Hassan BA, Shelemo MB, Nicholls PG, Lockwood DNJ., Erythema Nodosum Leprosum International Study Group. A leprosy clinical severity scale for erythema nodosum leprosum: An international, multicentre validation study of the ENLIST ENL Severity Scale. PLoSNegl Trop Dis. 2017 Jul;11(7): e0005716.
39. Rea TH, Jerskey RS. Clinical and histologic variations among thirty patients with Lucio’s phenomenon and pure and primitive diffuse lepromatosis (Latapi’slepromatosis). Int J Lepr Other Mycobact Dis. 2005 Sep;73(3):169-88.
40. White C, Franco-Paredes C. Leprosy in the 21st century. Clin Microbiol Rev. 2015 Jan;28(1):80-94.
41. Negera E, Bobosha K, Walker SL, Endale B, Howe R, Aseffa A, Dockrell HM, Lockwood DN. New Insight into the Pathogenesis of Erythema Nodosum Leprosum: The Role of Activated Memory T-Cells. Front Immunol. 2017; 8:1149.
42. Negera E, Walker SL, Bekele Y, Dockrell HM, Lockwood DN. Increased activated memory B-cells in the peripheral blood of patients with erythema nodosum leprosum reactions. PLoSNegl Trop Dis. 2017 Dec;11(12):e0006121.
43. Polycarpou A, Walker SL, Lockwood DN. A Systematic Review of Immunological Studies of Erythema Nodosum Leprosum. Front Immunol. 2017; 8:233.
44. Silva EA, Iyer A, Ura S, Lauris JR, Naafs B, Das PK, Vilani-Moreno F. Utility of measuring serum levels of anti-PGL-I antibody, neopterin and C-reactive protein in monitoring leprosy patients during multi-drug treatment and reactions. Trop Med Int Health. 2007 Dec;12(12):1450-8.
45. Walker SL, Sales AM, Butlin CR, Shah M, Maghanoy A, Lambert SM, Darlong J, Rozario BJ, Pai VV, Balagon M, Doni SN, Hagge DA, Nery JAC, Neupane KD, Baral S, Sangma BA, Alembo DT, Yetaye AM, Hassan BA, Shelemo MB, Nicholls PG, Lockwood DNJ., Erythema Nodosum Leprosum International Study Group. A leprosy clinical severity scale for erythema nodosum leprosum: An international, multicentre validation study of the ENLIST ENL Severity Scale. PLoS Negl Trop Dis. 2017 Jul;11(7): e0005716. [PMC free article] [PubMed]
46. Rea TH, Jerskey RS. Clinical and histologic variations among thirty patients with Lucio’s phenomenon and pure and primitive diffuse lepromatosis (Latapi’s lepromatosis). Int J Lepr Other Mycobact Dis. 2005 Sep;73(3):169-88. [PubMed]
47. White C, Franco-Paredes C. Leprosy in the 21st century. Clin Microbiol Rev. 2015 Jan;28(1):80-94. [PMC free article] [PubMed]
48. Negera E, Bobosha K, Walker SL, Endale B, Howe R, Aseffa A, Dockrell HM, Lockwood DN. New Insight into the Pathogenesis of Erythema Nodosum Leprosum: The Role of Activated Memory T-Cells. Front Immunol. 2017; 8:1149. [PMC free article] [PubMed]
49.Negera E, Walker SL, Bekele Y, Dockrell HM, Lockwood DN. Increased activated memory B-cells in the peripheral blood of patients with erythema nodosum leprosum reactions. PLoS Negl Trop Dis. 2017 Dec;11(12):e0006121. [PMC free article] [PubMed]
49. Polycarpou A, Walker SL, Lockwood DN. A Systematic Review of Immunological Studies of Erythema Nodosum Leprosum. Front Immunol. 2017; 8:233. [PMC free article] [PubMed]
50. Silva EA, Iyer A, Ura S, Lauris JR, Naafs B, Das PK, Vilani-Moreno F. Utility of measuring serum levels of anti-PGL-I antibody, neopterin and C-reactive protein in monitoring leprosy patients during multi-drug treatment and reactions. Trop Med Int Health. 2007 Dec;12(12):1450-8. [PubMed]
51. Gillis T, Vissa V, Matsuoka M, Young S, Richardus JH, Truman R, Hall B, Brennan P., Ideal Consortium Partners. Characterisation of short tandem repeats for genotyping Mycobacterium leprae. Lepr Rev. 2009 Sep;80(3):250-60. [PubMed]
52. Brennan PJ. Skin test development in leprosy: progress with first-generation skin test antigens, and an approach to the second generation. Lepr Rev. 2000 Dec;71 Suppl: S50-4. [PubMed]
53. Mitra DK, Joshi B, Dinda AK, Rai AK, Girdhar BK, Katoch K, Bindra MS, Sengupta U. Induction of lepromin reactivity in cured lepromatous leprosy patients: impaired chemokine response dissociates protective immunity from delayed type hypersensitivity. Microbes Infect. 2009 Dec;11(14-15):1122-30. [PubMed]
54. Kaplan G, Laal S, Sheftel G, Nusrat A, Nath I, Mathur NK, Mishra RS, Cohn ZA. The nature and kinetics of a delayed immune response to purified protein derivative of tuberculin in the skin of lepromatous leprosy patients. J Exp Med. 1988 Nov 01;168(5):1811-24. [PMC free article] [PubMed]
55. Butlin CR, Soares D, Neupane KD, Failbus SS, Roche PW. IgM anti-phenolic glycolipid-I antibody measurements from skin-smear sites: correlation with venous antibody levels and the bacterial index. Int J Lepr Other Mycobact Dis. 1997 Dec;65(4):465-8. [PubMed]
56. Bührer SS, Smits HL, Gussenhoven GC, van Ingen CW, Klatser PR. A simple dipstick assay for the detection of antibodies to phenolic glycolipid-I of Mycobacterium leprae. Am J Trop Med Hyg. 1998 Feb;58(2):133-6. [PubMed]
57. Oskam L, Slim E, Bührer-Sékula S. Serology: recent developments, strengths, limitations and prospects: a state-of-the-art overview. Lepr Rev. 2003 Sep;74(3):196-205. [PubMed]
58. Douglas JT, Celona RV, Abalos RM, Madarang MG, Fajardo T. Serological reactivity and early detection of leprosy among contacts of lepromatous patients in Cebu, the Philippines. Int J Lepr Other Mycobact Dis. 1987 Dec;55(4):718-21. [PubMed]
59. Ulrich M, Smith PG, Sampson C, Zuniga M, Centeno M, Garcia V, Manrique X, Salgado A, Convit J. IgM antibodies to native phenolic glycolipid-I in contacts of leprosy patients in Venezuela: epidemiological observations and a prospective study of the risk of leprosy. Int J Lepr Other Mycobact Dis. 1991 Sep;59(3):405-15. [PubMed].
60. Ulrich M, Smith PG, Sampson C, Zuniga M, Centeno M, Garcia V, Manrique X, Salgado A, Convit J. IgM antibodies to native phenolic glycolipid-I in contacts of leprosy patients in Venezuela: epidemiological observations and a prospective study of the risk of leprosy. Int J Lepr Other Mycobact Dis. 1991 Sep;59(3):405-15. [PubMed]